



## Martina Pagliuca

**Date of birth:** 04/12/1991 | **Nationality:** Italian | **Gender:** Female | **Phone number:** (+39) 3202952488 (Mobile) | **Phone number:** (+33) 785337283 (Mobile) | **Email address:**

[m.pagliuca@ssmeridionale.it](mailto:m.pagliuca@ssmeridionale.it) | **Email address:** [Martina.PAGLIUCA@gustaveroussy.fr](mailto:Martina.PAGLIUCA@gustaveroussy.fr) |

**Email address:** [martina.pagliuca@unina.it](mailto:martina.pagliuca@unina.it) | **Email address:** [martinapagliuca@gmail.com](mailto:martinapagliuca@gmail.com) |

**Website:** <https://www.scopus.com/authid/detail.uri?authorId=57130751300> | **Website:**

<https://orcid.org/0000-0001-8114-2577> | **LinkedIn:**

<https://it.linkedin.com/in/martina-pagliuca-7654451b0> | **X:** [https://twitter.com/marti\\_pagliuca](https://twitter.com/marti_pagliuca) |

**WhatsApp Messenger:** +393202952488 |

**Address:** Scuola Superiore Meridionale, via Mezzocannone 4, 80134, Naples, Italy (Work)

**Address:** Bâtiment de Médecine Moléculaire (B2M) - Institut Gustave Roussy, 32 Rue Camille Desmoulins, 94800, Villejuif, France (Secondary work address)

### ABOUT ME

Medical Doctor, Medical Oncologist, Researcher, PhD student

### WORK EXPERIENCE

20/12/2024 – CURRENT Naples, Italy

**RESEARCHER (RTT) SCUOLA SUPERIORE MERIDIONALE**

10/10/2021 – CURRENT Villejuif - Paris, France

**RESEARCH FELLOW GUSTAVE ROUSSY CANCER CAMPUS**

Breast Cancer Survivorship Research Group  
Molecular Predictors and New Targets in Oncology Unit

11/2017 – 12/2022 Naples, Italy

**MEDICAL ONCOLOGY RESIDENCY UNIVERSITY OF NAPLES "FEDERICO II"**

Medical Oncology - Diagnostic and Therapeutic Day Hospital and Outpatient Clinics (Breast, Melanoma, Hereditary Cancer Genetics, Gynecological, Gastrointestinal, Urological, CNS, Rare Tumors, Lung Cancer), Oncology Ward, Clinical Research activities, Data Collection and Analysis

09/2020 – 29/09/2021 Naples, Italy

**SPECIALIST MEDICAL TRAINING ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G.PASCALE**

Experimental Breast Clinical Oncology Unit - Therapeutic Day Hospital, Breast Cancer Ward, Multidisciplinary Team Activities, Data Collection and Analysis

11/2018 – CURRENT Aversa, Italy

**OUT-OF-HOURS MEDICAL SERVICE ASL CASERTA**

Medical Doctor in out-of-hours service

18/04/2021 – 29/09/2021 Italy

**COVID-19 VACCINATION PROGRAMME ASL CASERTA**

Medical Doctor

## ● EDUCATION AND TRAINING

---

06/03/2025 – CURRENT Naples, Italy

**MASTER IN STATISTICAL METHODS FOR CLINICAL RESEARCH AND EPIDEMIOLOGY** University "Luigi Vanvitelli"

---

11/2023 – CURRENT Villejuif, France

**PHD IN CANCÉROLOGIE, BIOLOGIE, MÉDECINE, SANTÉ** University Paris-Saclay

---

11/2022 – CURRENT Naples, Italy

**PHD IN CLINICAL AND TRANSLATIONAL ONCOLOGY** Scuola Superiore Meridionale (SSM)

---

01/11/2021 – 31/10/2022 France

**DIPLOME UNIVERSITAIRE EUROPÉEN DE RECHERCHE TRANSLATIONNELLE ET CLINIQUE EN CANCÉROLOGIE - DUERTECC** University Paris Saclay

---

01/11/2021 – 31/10/2022 France

**DIPLOME UNIVERSITAIRE DE CARCINOLOGIE CLINIQUE - DUCC** University Paris Saclay

---

12/2017 – 12/2022 Naples, Italy

**MEDICAL ONCOLOGY RESIDENCY** University of Naples "Federico II"

---

27/11/2017

**WINNER OF PUBLIC NATIONAL COMPETITION FOR ACCESS TO MEDICAL RESIDENCY** Ministero dell'Istruzione, dell'Università e della Ricerca. Ranked 32 out of 14435 participants

---

01/2017 Italy

**MEDICAL LICENSE 270/270** University of Naples "Federico II"

---

2010 – 2016 Italy

**MEDICAL DEGREE 110/110 CUM LAUDE** University of Naples "Federico II"

---

2004 – 2010 Aversa, Italy

**HIGH SCHOOL DIPLOMA 100/100** Liceo Classico Statale "Domenico Cirillo"

---

## ● LANGUAGE SKILLS

---

Mother tongue(s): **ITALIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
<b>ENGLISH</b>	C1	C1	C1	C1	C1
<b>FRENCH</b>	C1	C1	B2	C1	B1

---

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

## ● PROFESSIONAL SKILLS

---

05/2024 – CURRENT

**Editorial Board Member of BMC Cancer**

---

02/10/2023 – 04/10/2023

**Advanced programming with SAS**

---

Institut national de la santé et de la recherche médicale

10/07/2023

**GCP Training**

---

ICH GCP  
Score: 100%

21/02/2022 – 14/06/2023

## **Elaboration of Guidelines according to GRADE Method**

---

Organized by DEP Lazio and AIOM

06/2021

## **Common European Framework of Reference for Languages (CEFR) Level C1**

---

Academic IELTS: Overall Band Score 7.0  
British Council - idp - Cambridge Assessment English

04/2021

## **Introduction to Systematic Review and Meta- Analysis**

---

Johns Hopkins University  
Online course

04/2020 – CURRENT

## **Review Editor for Frontiers in Oncology**

---

Breast Cancer specialty section

05/2019

## **GCP Compliance Training**

---

HCPs V2.0

26/02/2019 – 27/02/2019

## **Specific training course on health and safety at work**

---

Organized by AOU "Federico II", Naples, pursuant to Legislative Decree 81/08 and ss.ii.mm. of the State-Region Agreement of 21 December 2011 and the State-Regions Agreement of 7 July 2016

02/2016

## **Pediatric Basic Life Support & Defibrillation (PBLIS-D)**

---

Certification awarded by GIEC - American Heart Association authorized training center

## ● **CLINICAL RESEARCH**

---

01/2025 – CURRENT

## **GIM36 (VOICE) Assessing prevalence of financial burden and impact of cancer on financial toxicity in patients with early-stage breast Cancer**

---

Principal Investigator

07/06/2021 – CURRENT

## **A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-Breast12)**

---

Sub Investigator

09/05/2021 – CURRENT

## **A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)**

---

Sub Investigator

28/04/2021 – CURRENT

## **GIM14 (BIO-META) Evaluation of medical treatments (chemotherapy, hormonal therapy and biological therapies) in metastatic breast cancer patients according to biologic subtype and line of treatment.**

---

Sub Investigator

2021 – CURRENT

**A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)**

---

Sub Investigator

20/11/2019 – CURRENT

**A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)**

---

Sub Investigator

06/11/2019 – CURRENT

**GIM24 (PALBO-BP) Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial - Palbo-BP**

---

Sub Investigator

29/10/2019 – CURRENT

**FeDeriCa A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer**

---

Sub Investigator

06/06/2019 – 30/01/2020

**CABACARE CABazitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.**

---

Sub Investigator

17/10/2019

**DURWIN A perspective, multi-center, open-label, single arm, two-step phase II study of DURvalumab (MEDI4736) in patients With poor performance status as first-line treatment for advanced urothelial cancer**

---

Sub Investigator

29/09/2016 – CURRENT

**QUASAR Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial**

---

Study Coordinator

## ● PUBLICATIONS

---

2025

[\*\*Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model\*\*](#)

---

**Martina Pagliuca, MD**, Julie Havas, MSc, Emilie Thomas, MSc, Youenn Drouet, PhD, Davide Soldato, MD, Maria Alice Franzoi, MD, Joana Ribeiro, MD, Camila K Chiodi, MD, Emma Gillanders, BA, Barbara Pistilli, MD, Gwenn Menvielle, PhD, Florence Joly, MD, Florence Lerebours, MD, Olivier Rigal, MD, Thierry Petit, MD, PhD, Sylvie Giacchetti, MD, Florence Dalenc, MD, PhD, Johanna Wassermann, MD, MSPH, Olivier Arsene, MD, Anne Laure Martin, PhD, Sibille Everhard, PhD, Olivier Tredan, MD, PhD, Sandrine Boyault, MSc, Michelino De Laurentiis, MD, PhD, Alain Viari, PhD, Jean Francois Deleuze, PhD, Aurelie Bertaut, MD, PhD, Fabrice André, MD, PhD, Ines Vaz-Luis, MD, PhD, Antonio Di Meglio, MD, PhD

2024

[CAR-T cell therapy for breast cancer: Current status and future perspective](#)

---

Giuseppe Buono, Monica Capozzi, Roberta Caputo, Vincenzo Di Lauro, Daniela Cianniello, Michela Piezzo, Stefania Cocco, Claudia Martinelli, Annarita Verrazzo, Margherita Tafuro, Claudia Calderaio, Alessandra Calabrese, Francesco Nuzzo, **Martina Pagliuca**, Michelino De Laurentiis

Cancer Treatment Reviews

2024

[A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later](#)

---

A. Di Meglio • J. Havas • **M. Pagliuca** • M.A. Franzoi • D. Soldato • C.K. Chiodi • E. Gillanders • F. Dubuisson • V. Camara-Clayette • B. Pistilli • J. Ribeiro • F. Joly • P.H. Cottu • O. Tredan • A. Bertaut • P.A. Ganz • J. Bower • A.H. Partridge • A.L. Martin • S. Everhard • S. Boyault • S. Brutin • F. André • S. Michiels • C. Pradon • I. Vaz-Luis

Annals of Oncology

2024

[Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer](#)

---

F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier, O. Trédan, E. Volant, J.-S. Frenel, S. Ladoire, W. Jacot, M. Jamelot, H. Foka Tichoue, A. Patsouris, L. Teixeira, F.-C. Bidard, D. Loirat, M. Brunet, C. Levy, C. Bailleux, B. Cabarro, A. Deleuze, L. Uwer, E. Deluche, T. Grellety, C. Franchet, F. Fiteni, H. Bischoff, R. Vion, **M. Pagliuca**, B. Verret, S. Bécourt, T. Reverdy, A. de Nonneville & F. Dalenc

British Journal of Cancer

2024

[Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis](#)

---

Buonaiuto R, Caltavitturo A, Tafuro M, Longobardi A, Pavone G, De Santis P, Caputo R, De Angelis C, Del Mastro L, Puglisi F, Giuliano M, Arpino G, **Pagliuca M**, De Laurentiis M

The Breast

2024

[Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium](#)

---

Franzoi MA, Ferreira A, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM, Polastro L, Grellety T, Artignan X, Le Du K, **Pagliuca M**, Nouhaud E, Autheman M, André F, Basch E, Metzger O, Ferté C, Di Palma M, Scotté F, Vaz-Luis I

The Lancet Regional health - Europe

2024

[Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer](#)

---

Soldato S, Michiels S, Havas J, Di Meglio A, **Pagliuca M**, Franzoi MA, Pistilli B, Iyengar NM, Cottu P, L'Erebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, MArtin AL, André F, Vaz-Luis I, Jones LW

Journal of Clinical Oncology

2024

[International Society for Extracellular Vesicles workshop. QuantitatEVs: Multiscale analyses, from bulk to single extracellular vesicle](#)

---

Basso M, Gori A, Nardella C, Palviainen M, Holcar M, Sotiropoulos I, Bobis-Wozowicz S, D'Agostino VG, Casarotto E, Ciani Y, Suetsugu S, Gualerzi A, Martin-Jaular L, Boselli D, Kashkanova A, Parisse P, Lippens L, **Pagliuca M**, Blessing M, Frigerio R, Fourniols T, Meliciano A, Fietta A, Fioretti PV, Soroczyńska K, Picciolini S, Salviano-Silva A, Bergese P, Zocco D, Chiari M, JensterG, Waldron L, Milosavljevic A, Nolan J, Monopoli MP, Witwer KW, Bussolati B, Di Vizio D, Falcon Perez J, Lenassi M, Cretich M, Demichelis F

2023  
[\*\*Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations\*\*](#)

---

D'Arienzo A, Verrazzo A, **Pagliuca M**, Napolitano F, Parola S, Viggiani M, Caputo R, Puglisi F, Giuliano M, Del Mastro L, Arpino G, De Laurentiis M, Montemurro F

EClinicalMedicine

2023  
[\*\*Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion\*\*](#)

---

Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, **Pagliuca M**, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M

Future Oncology

2023  
[\*\*Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report\*\*](#)

---

Caputo R, **Pagliuca M**, Pensabene M, Parola S, De Laurentiis M

Frontiers in Oncology

2023  
[\*\*Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype\*\*](#)

---

Aldo Caltavitturo, Roberto Buonaiuto, Erica Pietroluongo, Rocco Morra, Fabio Salomone, Pietro De Placido, **Martina Pagliuca**, Angelo Vaia, Margaret Ottaviano, Marianna Tortora, Sabino De Placido, Giovannella Palmieri, Mario Giuliano

Biomedicines

2022  
[\*\*New steps on an old path: Novel estrogen receptor inhibitors in breast cancer\*\*](#)

---

**Pagliuca M**, Donato M, Lagodin D'Amato A, Rosanova M, Russo AOM, Scafetta R, De Angelis C, Trivedi MV, André F, Arpino G, Del Mastro L, De Laurentiis M, Puglisi F, Giuliano M

Critical Reviews in Oncology/Hematology

2021  
[\*\*Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie.\*\*](#)

---

De Angelis C, Nardelli C, Concolino P, **Pagliuca M**, Setaro M, De Paolis E, De Placido P, Forestieri V, Scaglione GL, Ranieri A, Lombardo B, Pastore L, De Placido S, Capoluongo E.

Frontiers in Oncology

2020  
[\*\*Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists\*\*](#)

---

Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Contedua V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, **Pagliuca M**, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierio PA

Journal for ImmunoTherapy of Cancer

2020

[\*\*Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis\*\*](#)

---

Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, **Pagliuca M**, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G

Cancers

2019

[\*\*Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis\*\*](#)

---

Buonerba C, Iaccarino S, Dolce P, **Pagliuca M**, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G.

Cancers

2019

[\*\*The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer\*\*](#)

---

**Pagliuca M**, Buonerba C, Fizazi K, Di Lorenzo G.

Drugs

2018

[\*\*Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib \(QUASAR\): Results of a Phase I Trial\*\*](#)

---

Buonerba C, De Placido P, Bruzzese D, **Pagliuca M**, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, Perri F, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G

Frontiers in Pharmacology

2017

[\*\*The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer\*\*](#)

---

Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, **Pagliuca M**, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G

Journal of Cancer

2017

[\*\*PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study\*\*](#)

---

Bosso D, **Pagliuca M**, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G

Medicine

2017

[\*\*Immunotherapy for penile cancer\*\*](#)

---

Buonerba C, **Pagliuca M**, Vitrone FM, Ascione I, Elefante I, Riccio V, Romano F, De Placido S, Di Lorenzo G

Future science OA

2016

[\*\*The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review\*\*](#)

---

Di Lorenzo G, De Placido S, **Pagliuca M**, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G

Expert Opinion on Biological Therapy

2016

## [Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature](#)

---

Di Lorenzo G, **Pagliuca M**, Perillo T, Benincasa A, Bosso D, De Placido S, Buonerba C

Medicine

2016

## [Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report](#)

---

Di Lorenzo G, **Pagliuca M**, Perillo T, Zarrella A, Verde A, De Placido S, Buonerba C

Medicine

### ● **AUTHOR**

---

2023

## [Complications - Lung metastases](#)

---

Chapter of the Textbook *Metastatic Breast Cancer - Treatment and Management*, Minerva Medica

07/2021

## [First-line therapy with atezolizumab in patient with triple-negative breast cancer without evidence of disease](#)

---

Chapter of the Textbook *Breast Cancer and Immunotherapy*, Edra

### ● **ABSTRACT AND POSTER**

---

## [Clinical characteristics and survival outcome of patients with early discontinuation of first-line \(1L\) cyclin-dependent kinase 4 and 6 inhibitors \(CDK4/6i\) therapy for HR+/HER2- advanced breast cancer: a nationwide, real-world study](#)

---

San Antonio Breast Cancer Symposium (SABCS) 2024 Abstract P1-08-12

**Martina Pagliuca**, Alexandre Lolivier, Benjamin Verret, Barbara Pistilli, Michelino De Laurentiis, Antonio Di Meglio, Stefan Michiels, Fabrice André, Stephanie Foulon

## [Genome-wide association study \(GWAS\) of aromatase inhibitor musculoskeletal toxicity \(AIMT\) among early-stage breast cancer \(BC\) survivors.](#)

---

San Antonio Breast Cancer Symposium (SABCS) 2024 Abstract PS15-02

Pietro Lapidari, Youenn Drouet, Emilie Thomas, Jérémie Jacquemin, Maria Alice Franzoi, **Martina Pagliuca**, Sophie Laurent, Chayma Bousrih, Maryam Lustberg, Olivier Tredan, Anne-laure Martin, Catherine Gaudin, Christelle Jouannaud, Marion Fournier, William Jacot, Marina Rousseau, Jean Francois Deleuze, Alain Viari, Ines Vaz-Luis, Antonio Di Meglio

## [Systemic inflammation, unhealthy behaviors, and cancer-related fatigue \(CRF\) among survivors of breast cancer \(BC\)](#)

---

ESMO Congress 2024 Abstract 1819MO DOI: [10.1016/j.annonc.2024.08.1915](https://doi.org/10.1016/j.annonc.2024.08.1915)

A. Di Meglio, J. Havas, **M. Pagliuca**, M.A. Franzoi, D. Soldato, B. Pistilli, F. Joly Lobbedez, P.H. Cottu, O. Tredan, A. Bertaut, P. Ganz, J. Bower, A.H. Partridge, A. Martin, S. Everhard, S. Boyault, S. Broutin, S. Michiels, C. Sarre-Pradon, I.V. Vaz Luis

## [Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity \(AIMT\) among patients \(pts\) with early breast cancer \(EBC\)](#)

---

ESMO Congress 2024 Abstract 1818MO DOI: [10.1016/j.annonc.2024.08.1914](https://doi.org/10.1016/j.annonc.2024.08.1914)

P. Lapidari, M. Lustberg, J. Havas, **M. Pagliuca**, C. Bousrih, C. Jouannaud, M. Fournier, W. Jacot, L. Vanlemmens, C. Kaderbhai, O. Tredan, C. Levy, A. Martin, C. Gaudin, G. Menvielle, M.A. Franzoi, I.V. Vaz Luis, A. Di Meglio

## [Trajectories of cancer-related behavioral symptoms \(CRBS\) burden after breast cancer \(BC\).](#)

---

2024 ASCO Annual Meeting Abstract #: 12038 DOI: [10.1200/JCO.2024.42.16\\_suppl.12038](https://doi.org/10.1200/JCO.2024.42.16_suppl.12038)



**Martina Pagliuca**, Julie Havas, Pietro Lapidari, Gwenn Menvielle, Leonor Fasse, Diane Boinon, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Marion Fournier, William Jacot, Laurence Vanlemmens, Coureche Kaderbhai, Florence Joly, Michelino De Laurentiis, Florian Scotte, Stefan Michiels, Maria Alice B Franzoi, Ines Maria Vaz Duarte Luis, Antonio Di Meglio

---

### **Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).**

---

2024 ASCO Annual Meeting Abstract #: 12009 DOI: 10.1200/JCO.2024.42.16\_suppl.12009

Antonio Di Meglio, Cécile Charles, Julie Havas, **Martina Pagliuca**, Pietro Lapidari, Gwenn Menvielle, Leonor Fasse, Diane Boinon, Aurelie Bardet, Alicia Larive, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Marion Fournier, William Jacot, Laurence Vanlemmens, Coureche Kaderbhai, Stefan Michiels, Maria Alice B Franzoi, Ines Vaz-Luis

---

### **Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.**

---

2024 ASCO Annual Meeting Abstract #: 12122 DOI: 10.1200/JCO.2024.42.16\_suppl.12122

Pietro Lapidari, Maryam B. Lustberg, Julie Havas, **Martina Pagliuca**, Maria Alice B Franzoi, Gwenn Menvielle, Barbara Pistilli, Christelle Jouannaud, Baptiste Sauterey, Olivier Tredan, Paul H. Cottu, Christelle Levy, Florence Lerebours, Sibille Everhard, Anne-Laure Martin, Ines Maria Vaz Duarte Luis, Antonio Di Meglio

---

### **Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling**

---

ESMO Breast Cancer 2024 Abstract 52P DOI: [10.1016/j.esmoop.2024.103059](https://doi.org/10.1016/j.esmoop.2024.103059)

F. Giugliano, J.R. Dixon Douglas, A. Tran Dien, **M. Pagliuca**, L. Minot, E. Rouleau, A. Bayle, G. Curigliano, B. Verret, A.A. Viansone, M.F. Mosele, B. Pistilli, F. André, A. Italiano, J.T.L. Ribeiro Mourato

---

### **The influence of ethnicity on cyclin-dependent kinase inhibitors efficacy: A systematic review and meta-analysis**

---

ESMO Breast Cancer 2024 Abstract 229P DOI: [10.1016/j.esmoop.2024.103251](https://doi.org/10.1016/j.esmoop.2024.103251)

R. Buonaiuto, A. Caltavuturo, **M. Pagliuca**, M. Tafuro, A. Longobardi, G. Pavone, P. De Santis, L. Del Mastro, F. Puglisi, M. Giuliano, G. Arpino, M. De Laurentiis

---

### **Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC).**

---

San Antonio Breast Cancer Symposium (SABCS) 2023 Abstract PO4-14-05 <https://doi.org/10.1158/1538-7445.SABCS23-PO4-14-05>

Antonio Di Meglio Emilie Thomas Youenn Drouet Jean-Baptiste Micol Davide Soldato Maria Alice Franzoi **Martina Pagliuca** Julie Havas Anne-Laure Martin Sibille Everhard Celine Besse Anne Boland Christophe Marzac Nathalie Droin Sandrine Boyault Marina Rousseau Olivier Trédan Paul Cottu Christelle Jouannaud Marion Fournier Laurence Vanlemmens CHARLES COUTANT Asma Dhaini Merimeche Baptiste Sauterey Florence Joly Mario Campone Florence Lerebours Marie-Ange Mouret-Reynier Olivier Rigal Thierry Petit Sophie Guillermet Antoine Arnaud Mahmoud Ibrahim Sylvie Giacchetti Florence Dalenc Johanna Wassermann Olivier Arsène Ariane Darut-Jouve Aurélie Bertaut Fabrice André Jean-Francois Deleuze Alain Viari Ines Vaz Luis

---

### **ATTITUDE - ATTRition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?**

---

ESMO Congress 2023 Abstract 2130P DOI: <https://doi.org/10.1016/j.annonc.2023.09.912>

C.K. Chiodi, E. Martin, M.A. Franzoi, **M. Pagliuca**, D. Soldato, P. Lapidari, A. Barbier, J. Havas, J. Arvis, D. Boinon, G. Menvielle, L. Golli, R. Desjardin, G. Jacob, I.V. Vaz Luis, A. Di Meglio

---

### **Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC)**

---

2023 ASCO Annual Meeting DOI: 10.1200/JCO.2023.41.16\_suppl.12087 Journal of Clinical Oncology 41, no. 16\_suppl (June 01, 2023) 12087-12087.

**Martina Pagliuca**, Julie Havas, Florence Lerebours, Olivier Rigal, Thierry Petit, Sylvie Giacchetti, Florence Dalenc, Johanna Wassermann, Olivier Arsene, Anne-Laure Martin, Sibille Everhard, Ines Maria Vaz Duarte Luis, Antonio Di Meglio

---

### **Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe**

---

2023 ASCO Annual Meeting DOI: 10.1200/JCO.2023.41.16\_suppl.1518 Journal of Clinical Oncology 41, no. 16\_suppl (June 01, 2023) 1518-1518.

Arlindo R. Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean, Joana M Ribeiro, Laura Polastro, Thomas Grellety, Xavier Artignan, Katell Le Du, **Martina Pagliuca**, Élodie Nouhaud, Maximilien Autheman, Fabrice Andre, Ethan Basch, Otto Metzger, Mario Di Palma, Florian Scotte, Ines Maria Vaz Duarte Luis Maria Alice B Franzoi

### **Single molecule localization microscopy for nanoscale detection of extracellular vesicles in cancer**

---

EACR 2023 Abstract #: 0885

M.Triki, **M. Pagliuca**, C. Schietroma, C. Butler, B. Verret, A. Italiano, F. André

### **Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)**

---

ESMO Breast Cancer 2023 Abstract 209P DOI: <https://doi.org/10.1016/j.esmooop.2023.101398>

C. De Angelis, **M. Pagliuca**, T. Gamucci, M. Mansutti, Z. Ballatore, M. De Laurentiis, R. Bordonaro, A. Pazzola, V. Leonardi, D. Bruzzese, A.M. Mosconi, C. Molica, S. Cinieri, A. Fabi, L. Del Mastro, F. Puglisi, S. de Placido, M. Giuliano, G. Arpino

### **Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)**

---

ESMO Breast Cancer 2023 Abstract 29P DOI: <https://doi.org/10.1016/j.esmooop.2023.101253>

J.T.M.L.M. Ribeiro, A. Tran Dien, L. Mignot, **M. Pagliuca**, E. Rassy, M.F. Mosele, T. Grinda, A.A. Viansone, A. Géraud, B. Verret, A. Bayle, B. Pistilli, F. André, A. Italiano

### **Single molecule localization microscopy for extracellular vesicles detection in cancer**

---

ESMO MAP Congress 2022 Abstract 38P DOI: <https://doi.org/10.1016/j.annonc.2022.09.039>

**M. Pagliuca**, M. Triki, C. Schietroma, C. Butler, B. Verret, A. Italiano, D. Planchard, A. Bayle, F. André, S. Delalogue

### **Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple negative breast cancer: A systematic review and meta-analysis**

---

ESMO Congress 2022 Abstract 258P DOI: <https://doi.org/10.1016/j.annonc.2022.07.297>

**M. Pagliuca**, L. Bencivenga, K. Komici, C. De Angelis, R. Caputo, F. Napolitano, D. Cianniello, V. Di Lauro, G. Rengo, S. De Placido, F. André, M. De Laurentiis

### **CDK4/6 inhibitors in hormone receptor-positive, HER2- negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches**

---

ESMO Breast Cancer 2022 Abstract 105P DOI: <https://doi.org/10.1016/j.annonc.2022.03.121>

S. Parola, V. Di Lauro, P. De Placido, V. Forestieri, G. Buono, C. von Arx, E. Pietroluongo, **M. Pagliuca**, D. Cianniello, R. Lauria, R. Caputo, G. Arpino, S. de Placido, M. Giuliano, M. De Laurentiis, C. De Angelis

### **Circulating tumor cells count in prostate cancer patients treated with enzalutamide: the LANZA Study.**

---

2019 AIOM National Congress Abstract#: E12 DOI: 10.1177/0300891619872589

Morra R., Zappavigna S., Facchini G., Ribera D., Morelli F., Luce A., Iaccarino S., Izzo M., Scafuri L., Riccio V., Costabile F., **Pagliuca M.**, Abate M., Carrano S., Rossetti S., Giuliano M., De Placido S., Caraglia M., Buonerba C., Di Lorenzo G.

### **Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.**

---

2017 ASCO Annual Meeting Abstract #: e16503 DOI: 10.1200/JCO.2017.35.15\_suppl.e16503

Carlo Buonerba, Guru Sonpavde, Gregory Russell Pond, **Martina Pagliuca**, Sabrina Rossetti, Gaetano Facchini, Sarah Scagliarini, Bruno Daniele, Piera Federico, Franco Morelli, Giacomo Carteni, Matteo Ferro, Giuseppe Lucarelli, Teresa Bellelli, Sabino De Placido, Giuseppe di Lorenzo

## **GRANTS AND PRIZES**

---

2025

### **BJClub AWARDS Best papers Under 40**

---

Breast Journal Club 2025

Naples, Italy

2024

## **Fellowship Program 2024**

---

Gilead

Research grant: 30.000 €

2024

## **2024 Conquer Cancer® Merit Award**

---

ASCO Foundation

2023

## **2023 Conquer Cancer® Merit Award**

---

ASCO Foundation

## **Winner of ESMO Travel Grants**

---

- ESMO Preceptorship on Metastatic Bladder and Kidney Cancer, Zurich, Switzerland, 2018
- ESMO Preceptorship on Head and Neck Cancer, Zurich, Switzerland, 2019
- ESMO Preceptorship on Colorectal Cancer, Lugano, Switzerland, 2019
- ESMO Advanced Course on Biomarkers for Precision Medicine, Zurich, Switzerland, 2021
- ESMO Preceptorship on Immuno Oncology, Zurich, Switzerland, 2022
- ESMO MAP Congress 2022, Amsterdam, Netherlands, 2022
- ESMO Breast Cancer 2023, Berlin, Germany, 2023
- ESMO MAP Congress 2023, Paris, France, 2023

## **● SPEAKER IN COURSES AND CONGRESSES**

---

07/03/2025

### **BJClub AWARDS - Best papers Under 40**

---

Breast Journal Club 2025

Naples, Italy

18/12/2024

### **Updates in Breast Cancer: Methodologically Relevant Studies**

---

Breast Cancer Academy: The Latest Updates from San Antonio  
Online

15/11/2024

### **Round Table - Multidisciplinary Management of Clinical Cases**

---

Innovation and Optimization in the Treatment of Metastatic Breast Cancer  
Caserta, Italy

11/10/2024

### **New ADCs for the Treatment of Triple-Negative Breast Cancer**

---

Young to Young 2024

Genova, Italy

21/06/2024

### **Application and Value of Patient-Reported Outcomes in the Management of Oncology Patients - Breast Cancer**

---

21<sup>st</sup> AIOM National Conference - Patient-Reported Outcomes

Bologna, Italy

12/06/2024

### **Adjuvant Treatment in Breast Cancer: State of the Art**

---

Breast Cancer Academy Meets... "Omic" Profiling

Online

24/05/2024

---

**CDK4/6 inhibitors resistance in breast cancer**

---

FIRST MEDITERRANEAN CONFERENCE on open issues and new waves in immunotherapy and targeted therapy  
Naples, Italy

21/05/2024

---

**State of the Art and Future Strategies of PARP Inhibitor Therapy from Early-Stage to Metastatic Setting**

---

Multidisciplinary Approach to Breast Neoplasms  
Online

22/03/2024

---

**The Oncologist's Perspective: Risk Assessment Using Clinical Parameters and Adjuvant Therapy**

---

Life 2 Women - Treatment of Patients with HR+ HER2- Breast Cancer from Adjuvant to Metastatic Setting  
Naples, Italy

07/07/2023

---

**A year of news: how clinical practice for breast cancers is changing**

---

Italian Association for Medical Oncology (AIOM) Young Oncologists Annual Congress 2023  
Perugia, Italy

12/05/2023

---

**Detection of treatment toxicity through remote monitoring**

---

ESMO Breast Cancer 2023  
Berlin, Germany

20/04/2023

---

**Locoregional therapies should always be combined with systemic therapy in oligometastatic disease - Cons**

---

Breast Journal Club 2023  
Rome, Italy

29/10/2022

---

**GIM12 - TYPHER clinical trial**

---

Italian Breast Group (Gruppo Italiano Mammella - GIM) Annual Meeting 2022  
Naples, Italy

21/06/2021

---

**Extended adjuvant endocrine therapy in high risk patients with early breast cancer**

---

BreaST-StayTuned 2021

21/11/2020

---

**Novel germline MLH1 gene variant in a family with Muir-Torre Syndrome**

---

ESMO Asia Virtual Congress 2020

23/06/2019

---

**Prolonged response with Nivolumab for second line treatment of mRCC**

---

Progressi nell'ambito del tumore renale: focus sul trattamento.  
Naples, Italy

07/05/2019

---

**Head and Neck Cancer: a multidisciplinary approach**

---

ESMO Preceptorship on Head and Neck Cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives.  
Zurich, Switzerland

23/11/2018

### **Systemic Therapy in Metastatic RCC**

---

ESMO Preceptorship on Metastatic Bladder and Kidney Cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives.  
Zurich, Switzerland

10/06/2018

### **First line Enzalutamide for CRPC patients**

---

Il tumore della prostata: a che punto siamo? Focus sull'efficacia del trattamento sistemico  
Naples, Italy

11/06/2017

### **Management of locally advanced prostate cancer**

---

Il tumore della prostata: a che punto siamo? Focus sulla terapia sistemica  
Naples, Italy

17/06/2016

### **Docetaxel rechallenge for mCRPC**

---

Progressi nell'ambito della diagnosi e cura del tumore prostatico - Focus sul trattamento  
Naples, Italy

## ● **MEMBERSHIPS**

---

08/2019 - CURRENT

### **ASCO American Society of Clinical Oncology**

---

01/2018 - CURRENT

### **ESMO European Society for Medical Oncology**

---

07/2022 - CURRENT

### **AACR American Association for Cancer Reserach**

---

05/2019 - CURRENT

### **AIOM Italian Association for Medical Oncology**

---

05/2020 - CURRENT

### **SIOG International Society of Geriatric Oncology**

---

02/2023 - CURRENT

### **ISEV International Society for Extracellular Vesicles**

---

02/2023 - CURRENT

### **EVIta Italian Society for Extracellular Vesicles**

---

## ● **INTERNATIONAL CONFERENCES**

---

10/12/2024 - 14/12/2024

### **San Antonio Breast Cancer Symposium 2024**

---

San Antonio, USA

13/09/2024 - 16/09/2024

### **ESMO Congress 2024**

---

Barcelona, Spain

31/05/2024 – 04/06/2024

**2024 ASCO Annual Meeting**

---

Chicago, USA

15/05/2024 – 17/05/2024

**ESMO Breast Cancer 2024**

---

Berlin, Germany

20/10/2023 – 24/10/2023

**ESMO Congress 2023**

---

Madrid, Spain

04/10/2023 – 06/10/2023

**ESMO Molecular Analysis for Precision Oncology Congress 2023**

---

Paris, France

02/06/2023 – 06/06/2023

**2023 ASCO Annual Meeting**

---

Chicago, USA

11/05/2023 – 13/05/2023

**ESMO Breast Cancer 2023**

---

Berlin, Germany

14/10/2022 – 16/10/2022

**ESMO Molecular Analysis for Precision Oncology Congress 2022**

---

Amsterdam, Netherlands

26/06/2022 – 27/06/2022

**ESMO Preceptorship on Immuno-Oncology From the essential of tumor immunology to clinical application**

---

Zurich, Switzerland

03/06/2022 – 07/06/2022

**2022 ASCO Annual Meeting**

---

Chicago, USA

03/05/2022 – 05/05/2022

**ESMO Breast Cancer 2022**

---

Berlin, Germany

29/04/2022 – 30/04/2022

**ESMO Virtual Advanced Course on Cancer Vaccines and Cellular Immunotherapy**

---

Online

07/03/2022 – 09/03/2022

**ESMO Targeted Anticancer Therapies Congress 2022**

---

Online

17/11/2021 – 23/11/2021

**ESMO Asia Virtual Oncology Week 2021**

---

Online

11/11/2021 – 12/11/2021

**ESMO Advanced Course on Biomarkers for Precision Medicine**

---

Zurich, Switzerland

06/10/2021 – 08/10/2021

**ESMO Molecular Analysis for Precision Oncology Virtual Congress 2021**

---

Online

03/06/2021 – 07/06/2021

**2021 ASCO Annual Meeting**

---

Online

26/05/2021 – 26/05/2021

**ESMO Virtual Preceptorship on Hereditary Cancer Genetics Multidisciplinary management, standards of care and future perspectives**

---

Online

04/05/2021 – 07/05/2021

**ESMO Breast Cancer Virtual Congress 2021**

---

Online

28/02/2021 – 01/03/2021

**ESMO TAT Virtual Congress 2021**

---

Online

08/12/2020 – 11/12/2020

**ESMO Immuno-Oncology Virtual Congress 2020**

---

Online

07/12/2020 – 10/12/2020

**2020 San Antonio Breast Cancer Symposium**

---

Online

29/11/2020 – 30/11/2020

**ESMO Virtual Preceptorship on Cancer Care in Elderly Patients: What all oncologists need to know Multidisciplinary management, standards of care and future perspectives**

---

Online

20/11/2020 – 22/11/2020

**ESMO Asia Virtual Congress 2020**

---

Online

12/11/2020 – 13/11/2020

**ESMO Virtual Preceptorship on Breast Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives**

---

Online

15/10/2020 – 17/10/2020

**ESMO Educational Virtual Congress 2020**

---

Online

09/10/2020 – 10/10/2020

**ESMO Molecular Analysis for Precision Oncology Virtual Congress 2020**

---

Online

18/09/2020 – 20/09/2020

**ESMO Virtual Congress 2020**

---

Online

20/08/2020 – 21/08/2020

**ESMO Academy Virtual Meeting 2020**

---

Online

07/08/2020 – 09/08/2020

**2020 ASCO Virtual Education Program**

---

Online

28/05/2020 – 30/05/2020

**2020 ASCO Virtual Scientific Program**

---

Online

22/05/2020 – 23/05/2020

**ESMO Breast Cancer Virtual Meeting 2020**

---

Online

14/11/2019 – 15/11/2019

**ESMO Preceptorship on Colorectal Cancer Multidisciplinary management, standards of care and future perspectives**

---

Lugano, Switzerland

26/09/2019 – 30/09/2019

**ESMO Congress 2019**

---

Barcelona, Spain

07/05/2019 – 08/05/2019

**ESMO Preceptorship on Head and Neck Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives**

---

Zurich, Switzerland

23/11/2018 – 24/11/2018

**ESMO Preceptorship on Metastatic Bladder and Kidney Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives**

---

Zurich, Switzerland

● **DIGITAL SKILLS**

---

Microsoft Office | Microsoft Powerpoint | Microsoft Excel | Outlook | Zoom | Social Media | programming with SAS | Review Manager (RevMan) | Rayyan | GRADE-PRO

● **DRIVING LICENCE**

---

**Driving Licence:** B